<DOC>
	<DOCNO>NCT00524745</DOCNO>
	<brief_summary>To demonstrate Gardasil速 vaccine , give girl 11-13 year age accord 1 3 alternative 3-dose schedule ( 0 , 3 , 9 month ; 0 , 6 , 12 month ; 0 , 12 , 24 month ) , result anti-HPV type 16 anti-HPV type 18 response 28 day post-dose 3 similar obtain vaccine give standard 3-dose schedule 0 , 2 , 6 month .</brief_summary>
	<brief_title>Immunogenicity Reactogenicity Alternative Schedules Gardasil</brief_title>
	<detailed_description>OBJECTIVES : Primary objective : To test hypothesis Gardasil速 vaccine , administer girl 11-13 year age accord 1 3 alternative 3-dose schedule ( 0,3,9 month ; 0,6,12 month ; 0,12,24 month ) , result anti-HPV 16 anti-HPV 18 response 28 day post-dose 3 similar obtain vaccine administer standard 3-dose schedule 0,2,6 month . Secondary objective : 1 . To test hypothesis Gardasil速 vaccine , administer girl 11-13 year age accord 1 3 alternative 3-dose schedule ( 0,3,9 month ; 0,6,12 month ; 0,12,24 month ) , result anti-HPV 6 anti-HPV 11 response 28 day post-dose 3 similar obtain vaccine administer standard 3-dose schedule 0,2,6 month . 2 . To describe safety profile administration Gardasil速 accord four schedule assess : ( ) immediate reactogenicity ( reaction within 30 minute injection ) ; ( ii ) solicit ( local reactogenicity fever ) unsolicited event occur first 7 day follow vaccination ; ( iii ) serious adverse event occur one month follow last dose vaccine ; ( iv ) death adverse event occur time determine vaccination-related .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . 1113 year age . 2 . Signed informed consent form ( parent 's &amp; daughter 's signature ) . 3 . Good health status . 4 . Able comply trial protocol . 5 . Plans stay current school duration study . 1 . Prior HPV vaccination 2 . Pregnant lactate intend become pregnant study period . 3 . Apparent moderate severe acute illness . 4 . Clinical history bleed disorder hemophilia , thrombocytopenia , anticoagulant therapy . 5 . Clinical history impair immune responsiveness , whether due use immunosuppressive therapy , genetic defect , HIV infection , cause . 6 . Hypersensitivity active substance excipients HPV vaccine , reaction vaccine receive past . 7 . Investigational drug investigational vaccine administer period 30 day 30 day dose HPV vaccine .</criteria>
	<gender>Female</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Gardasil</keyword>
	<keyword>Human Papillomavirus</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Cervical cancer</keyword>
</DOC>